|
Publication |
|
Combining SKY92 gene expression profiling and FISH (according to R2-ISS) defines ultra-high-risk Multiple Myeloma. Zhou X, Hofmann A, Engel B, Vogt C, Nerreter S, Tamamushi Y, Schmitt F, Leberzammer M, Stanojkovska E, Truger M, Xiao X, Riedhammer C, Steinhardt MJ, John M, Mersi J, Han S, Munawar U, Waldschmidt JM, Haferlach C, Einsele H, Rasche L, Kortüm KM. Hemasphere. 2025 Jan 23;9(1):e70078. doi: 10.1002/hem3.70078. eCollection 2025 Jan.
|
|
Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma. Haertle L, Munawar U, Hernández HNC, Arroyo-Barea A, Heckel T, Cuenca I, Martin L, Höschle C, Müller N, Vogt C, Bischler T, Del Campo PL, Han S, Buenache N, Zhou X, Bassermann F, Waldschmidt J, Steinbrunn T, Rasche L, Stühmer T, Martinez-Lopez J, Martin Kortüm K, Barrio S. Hemasphere. 2024 Jul 11;8(7):e110. doi: 10.1002/hem3.110. eCollection 2024 Jul.
|
|
Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study. Zhou X, Wagner V, Scheller L, Stanojkovska E, Riedhammer C, Xiao X, Steinhardt MJ, Vogt C, Nerreter S, Eisele F, John M, Munawar U, Kadel SK, Mersi J, Ruckdeschel A, Schimanski S, Haertle L, Waldschmidt JM, Han S, Topp M, Duell J, Einsele H, Riedel A, Kortüm KM, Rasche L. Br J Haematol. 2024 Sep;205(3):999-1010. doi: 10.1111/bjh.19515. Epub 2024 May 8.
|
|
Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma. Munawar U, Theuersbacher J, Steinhardt MJ, Zhou X, Han S, Nerreter S, Vogt C, Kurian S, Keller T, Regensburger AK, Teufel E, Mersi J, Bittrich M, Seifert F, Haider MS, Rasche L, Hillenkamp J, Einsele H, Kampik D, Kortüm KM, Waldschmidt JM. Haematologica. 2024 Nov 1;109(11):3670-3680. doi: 10.3324/haematol.2024.285205. Erratum to: Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma. Munawar U, Theuersbacher J, Steinhardt MJ, Zhou X, Han S, Nerreter S, Vogt C, Kurian S, Keller T, Regensburger AK, Teufel E, Mersi J, Bittrich M, Seifert F, Haider MS, Rasche L, Hillenkamp J, Einsele H, Kampik D, Kortüm KM, Waldschmidt JM. Haematologica. 2024 Nov 1;109(11):3828. doi: 10.3324/haematol.2024.285821.
|
|
Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma. Munawar U, Zhou X, Prommersberger S, Nerreter S, Vogt C, Steinhardt MJ, Truger M, Mersi J, Teufel E, Han S, Haertle L, Banholzer N, Eiring P, Danhof S, Navarro-Aguadero MA, Fernandez-Martin A, Ortiz-Ruiz A, Barrio S, Gallardo M, Valeri A, Castellano E, Raab P, Rudert M, Haferlach C, Sauer M, Hudecek M, Martinez-Lopez J, Waldschmidt J, Einsele H, Rasche L, Kortüm KM. Commun Biol. 2023 Dec 21;6(1):1299. doi: 10.1038/s42003-023-05683-4.
|
|
Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1. Zhou X, Han S, Cebulla N, Haertle L, Steinhardt MJ, Schirmer D, Runau E, Flamm L, Terhorst C, Jähnel L, Vogt C, Nerreter S, Teufel E, Stanojkovska E, Mersi J, Munawar U, Schindehütte M, Blum R, Reinhold AK, Scherf-Clavel O, Rittner HL, Pham M, Rasche L, Einsele H, Sommer C, Kortüm KM. Biomark Res. 2023 May 16;11(1):52. doi: 10.1186/s40364-023-00490-9.
|
|
High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex. Zhou X, Besse A, Peter J, Steinhardt MJ, Vogt C, Nerreter S, Teufel E, Stanojkovska E, Xiao X, Hornburger H, Haertle L, Lopez MM, Munawar U, Riedel A, Han S, Maurits E, Overkleeft HS, Florea B, Einsele H, Kortüm KM, Driessen C, Besse L, Rasche L. Haematologica. 2023 Jun 1;108(6):1628-1639. doi: 10.3324/haematol.2022.282225.
|
|
Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma. Haertle L, Buenache N, Cuesta Hernández HN, Simicek M, Snaurova R, Rapado I, Martinez N, López-Muñoz N, Sánchez-Pina JM, Munawar U, Han S, Ruiz-Heredia Y, Colmenares R, Gallardo M, Sanchez-Beato M, Piris MA, Samur MK, Munshi NC, Ayala R, Kortüm KM, Barrio S, Martínez-López J. Cancers (Basel). 2023 Jan 15;15(2):532. doi: 10.3390/cancers15020532.
|
|
Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma. Haertle L, Barrio S, Munawar U, Han S, Zhou X, Simicek M, Vogt C, Truger M, Fernandez RA, Steinhardt M, Weingart J, Snaurova R, Nerreter S, Teufel E, Garitano-Trojaola A, Da Viá M, Ruiz-Heredia Y, Rosenwald A, Bolli N, Hajek R, Raab P, Raab MS, Weinhold N, Haferlach C, Haaf T, Martinez-Lopez J, Einsele H, Rasche L, Kortüm KM. Clin Cancer Res. 2023 Jan 4;29(1):279-288. doi: 10.1158/1078-0432.CCR-22-1161.
|
|
Unraveling the genetic complexities of combined retinal dystrophy and hearing impairment. Bahena P, Daftarian N, Maroofian R, Linares P, Villalobos D, Mirrahimi M, Rad A, Doll J, Hofrichter MAH, Koparir A, Röder T, Han S, Sabbaghi H, Ahmadieh H, Behboudi H, Villanueva-Mendoza C, Cortés-Gonzalez V, Zamora-Ortiz R, Kohl S, Kuehlewein L, Darvish H, Alehabib E, Arenas-Sordo ML, Suri F, Vona B, Haaf T. Hum Genet. 2021 Jun 20. doi: 10.1007/s00439-021-02303-1. Online ahead of print.
|
|
Cereblon Enhancer Methylation and IMiD Resistance in Multiple Myeloma. Haertle L, Barrio S, Munawar U, Han S, Zhou X, Vogt C, Alonso R, Bittrich M, Ruiz-Heredia Y, Da-Via M, Zovko J, Garitano-Trojaola A, Bolli N, Ruckdeschel A, Stühmer T, Chatterjee M, Kull M, Krönke J, Agirre X, Martin-Subero I, Raab P, Einsele H, Rasche L, Martinez-Lopez J, Haaf T, Kortüm KM. Blood. 2021 Jun 11:blood.2020010452. doi: 10.1182/blood.2020010452. Online ahead of print.
|
|
| | Last update Publications 25.01.2025 |
|